Investigational drug · Phase 2
INNA-051
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Viral Respiratory Infection, Viral Respiratory Illnesses.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "INNA-051"
First trial start
2025
Dec 4, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "INNA-051", any sponsor or status.
Conditions studied
As listed on its trial records.
- Viral Respiratory Infection
- Viral Respiratory Illnesses
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "INNA-051" as an intervention, largest first.
- A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of AgePivotal-lookingRecruiting
ENA Respiratory Pty LtdIndustry
NCT07222670 · 1,100 participants (planned) · Start Dec 4, 2025 · Primary completion Mar 12, 2027
Drug: INNA-051 · For: Viral Respiratory Infection; Viral Respiratory Illnesses
Sites: Baltimore, Maryland; Bethesda, Maryland; College Park, Maryland · 6 sites in all
- INNA-051 Influenza Challenge StudyPivotal-lookingCompleted
ENA Respiratory Pty LtdIndustry
NCT05255822 · 123 participants · Start Feb 28, 2022 · Primary completion Aug 23, 2022
Drug: INNA-051 · For: Influenza Prophylaxis
Sites: London, United Kingdom
ENA Respiratory Pty LtdIndustry
NCT05118763 · 0 participants · Start Mar 1, 2022 · Primary completion Dec 31, 2022
Drug: INNA-051 · For: COVID-19 Pandemic
Newest research
PubMed records naming it or its code names, newest first.
- Priming mucosal pathogen-agnostic innate immunity with an intranasal TLR2/6 agonist in an aged population.
Mercuri FA, Zhuang A, McQuilten HA, et al. · ERJ Open Res 2025
- Discovery and development of INNA-051, a TLR2/6 agonist for the prevention of complications resulting from viral respiratory infections.
Mercuri FA, Anderson GP, Miller BE, et al. · Antiviral Res 2025
- Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology.
Mercuri FA, White S, McQuilten HA, et al. · ERJ Open Res 2024
- Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.
Proud PC, Tsitoura D, Watson RJ, et al. · EBioMedicine 2021
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.